Product Categories

PARP Poly (ADP-ribose) Polymerase

Compare PARP Inhibitors

Research Area
Research Area

▪ PARP1 Inhibitors ▪ PARP2 Inhibitors ▪ Pan-PARP Inhibitors

▪ New Product

PARP Inhibitors (12)
water-soluble

Cat.No.	Product Name	Information	Product Citations	Customer Reviews
S1060	Olaparib (AZD2281)	Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively.	Cell, 2011, 145(4), 529-542 Nat Chem Biol, 2012, 8(11):905-12 Nat Struct Mol Biol, 2012, 19(4):417-23
S1004	ABT-888 (Veliparib)	ABT-888 (Veliparib, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM, respectively.	Cancer Res, 2011, 71(14), 4944-4954 Nucleic Acids Res, 2013, ahead of print Clin Cancer Res, 2012, 18(21):5878-87
S1098	Rucaparib (AG-014699 , PF-01367338)	Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM.	Nature, 2011, 470(7334), 419-423 Cancer Lett, 2012, 319(2), 232-241 Nucl Med Commun, 2011, 32(11):1046-51
S1087	Iniparib (BSI-201)	BSI-201 (Iniparib, SAR240550) is a PARP1 inhibitor.	Neuroscience, 2010, 171(4), 1256-1264
S2197	A-966492	A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.
S7029	AZD2461	AZD2461 is a novel PARP inhibitor with potential to bypass Pgp-mediated resistance to Olaparib.
S7048	BMN 673	BMN 673 is a novel PARP inhibitor with IC50 of 0.58 nM.
S8038	UPF 1069	UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM.
S2178	AG14361	AG14361 is a potent inhibitor of PARP1 with K_i of < 5 nM.
S1132	INO-1001	INO-1001 is a potent inhibitor of PARP with IC50 of 50 nM and a mediator of oxidant-induced myocyte dysfunction during reperfusion.

Inhibitory Selectivity
Solubility

Cat.No.	Product Name	Solubility (25°C)
Cat.No.	Product Name	Water	DMSO	Ethanol
S1060	Olaparib (AZD2281)	<1 mg/mL	87 mg/mL	<1 mg/mL
S1004	ABT-888 (Veliparib)	<1 mg/mL	17 mg/mL	<1 mg/mL
S1098	Rucaparib (AG-014699 , PF-01367338)	<1 mg/mL	84 mg/mL	<1 mg/mL
S1087	Iniparib (BSI-201)	<1 mg/mL	58 mg/mL	28 mg/mL
S2197	A-966492	<1 mg/mL	65 mg/mL	<1 mg/mL
S7029	AZD2461	<1 mg/mL	79 mg/mL	31 mg/mL
S7048	BMN 673	<1 mg/mL	96 mg/mL	96 mg/mL
S8038	UPF 1069	<1 mg/mL	56 mg/mL	<1 mg/mL
S2178	AG14361	<1 mg/mL	12 mg/mL	<1 mg/mL
S1132	INO-1001	<1 mg/mL	27 mg/mL	27 mg/mL

Tags: PARP inhibition | PARP cancer | PARP inhibitor cancer | PARP signaling | PARP activity | PARP assay | PARP activity | PARP inhibitor trial | PARP activation | PARP inhibitors clinical trials | FDA approval PARP inhibitor | PARP inhibitor drugs | PARP phosphorylation | PARP inhibitor review